A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with PembrolizumabGil Awada, Bart Neyns, Kelly Schats et al.|Cancers|2021Cited by 36
Baseline total metabolic tumor volume assessed by 18FDG-PET/CT predicts outcome in advanced melanoma patients treated with pembrolizumabGil Awada, Bart Neyns, İsa Aykut Özdemir et al.|Annals of Oncology|2018Cited by 4
Baseline biomarkers correlated with outcome in advanced melanoma treated with pembrolizumab monotherapy.Gil Awada, Bart Neyns, Julia Katharina Schwarze et al.|Journal of Clinical Oncology|2020Cited by 3
High total metabolic tumor volume on 18F-FDG-PET/CT correlates with lack of immune response in advanced melanoma patients treated with pembrolizumab.Odrade Gondry, Marleen Keyaerts, Gil Awada et al.|Unknown|2020Cited by 0